The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

There was an increase in the hepatic fat fraction, the long-term consequences of which are unknown, says Robert Rosenson.

In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.

The BMJ cited several issues with the PREVENT-TAHA8 study data, concluding that the “results may not be reliable.” ...

The answer is very clear that if you have MI and preserved EF, there is no benefit of using a beta-blocker. Sripal Bangalore ...

NEW ORLEANS, LA—Complete revascularization in patients presenting with ACS and multivessel coronary artery disease ...

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

The hope is using AI to judge outcomes will ease the high cost and complexity of running big clinical trials, say researchers.

The device may help boost early detection of HFrEF for people living in low-resource settings where echo is scarce.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

The drug, given as a weekly subcutaneous injection, reduced both triglycerides and liver fat in the phase II trial.